Serina Therapeutics, Inc. Increase (Decrease) in Due to Related Parties
Serina Therapeutics, Inc. (SER) reported Increase (Decrease) in Due to Related Parties of -$66.00 thousand for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDueToRelatedParties · last filed 2024-08-09
- Serina Therapeutics, Inc. increase (decrease) in due to related parties for the quarter ending 2023-12-31 was $102.00K, a 29.66% decline year-over-year.
- Serina Therapeutics, Inc. increase (decrease) in due to related parties for the quarter ending 2023-09-30 was -$219.00K, a 586.67% decline year-over-year.
- Serina Therapeutics, Inc. increase (decrease) in due to related parties for the quarter ending 2023-06-30 was $125.00K, a 171.74% increase year-over-year.
- Serina Therapeutics, Inc. increase (decrease) in due to related parties for the quarter ending 2023-03-31 was $61.00K, a 221.05% increase year-over-year.
- Serina Therapeutics, Inc. increase (decrease) in due to related parties for fiscal 2023 was $69.00K, a 72.94% decline from fiscal 2022.
- Serina Therapeutics, Inc. increase (decrease) in due to related parties for fiscal 2022 was $255.00K.
- Serina Therapeutics, Inc. increase (decrease) in due to related parties for fiscal 2020 was $15.00K.
- Serina Therapeutics, Inc. increase (decrease) in due to related parties for fiscal 2019 was -$68.00K.
| Period end | Increase (Decrease) in Due to Related Parties 3 month | Increase (Decrease) in Due to Related Parties 6 month | Increase (Decrease) in Due to Related Parties 9 month | Increase (Decrease) in Due to Related Parties 12 month |
|---|---|---|---|---|
| 2024-06-30 | -$66.00K 10-Q · filed 2024-08-09 | |||
| 2023-12-31 | $102.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | -$117.00K derived: sum of 2 quarters · filed 2024-03-22 | $8.00K derived: sum of 3 quarters · filed 2024-03-22 | $69.00K 10-K · filed 2024-03-22 |
| 2023-09-30 | -$219.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$94.00K derived: sum of 2 quarters · filed 2023-11-14 | -$33.00K 10-Q · filed 2023-11-14 | $112.00K derived: sum of 4 quarters · filed 2024-03-22 |
| 2023-06-30 | $125.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $186.00K 10-Q · filed 2023-08-14 | $331.00K derived: sum of 3 quarters · filed 2024-03-22 | $376.00K derived: sum of 4 quarters · filed 2024-03-22 |
| 2023-03-31 | $61.00K 10-Q · filed 2023-05-12 | $206.00K derived: sum of 2 quarters · filed 2024-03-22 | $251.00K derived: sum of 3 quarters · filed 2024-03-22 | $297.00K derived: sum of 4 quarters · filed 2024-03-22 |
| 2022-12-31 | $145.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $190.00K derived: sum of 2 quarters · filed 2024-03-22 | $236.00K derived: sum of 3 quarters · filed 2024-03-22 | $255.00K 10-K · filed 2024-03-22 |
| 2022-09-30 | $45.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $91.00K derived: sum of 2 quarters · filed 2023-11-14 | $110.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $46.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $65.00K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $19.00K 10-Q · filed 2023-05-12 | |||
| 2021-06-30 | $25.00K 10-Q · filed 2022-08-12 | |||
| 2020-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | -$63.00K derived: sum of 2 quarters · filed 2022-03-29 | -$102.00K derived: sum of 3 quarters · filed 2022-03-29 | $15.00K 10-K · filed 2022-03-29 |
| 2020-09-30 | -$62.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$101.00K derived: sum of 2 quarters · filed 2021-11-12 | $16.00K 10-Q · filed 2021-11-12 | -$239.00K derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$39.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $78.00K 10-Q · filed 2021-08-13 | -$177.00K derived: sum of 3 quarters · filed 2021-08-13 | $81.00K derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | $117.00K 10-Q · filed 2021-05-17 | -$138.00K derived: sum of 2 quarters · filed 2021-05-17 | $120.00K derived: sum of 3 quarters · filed 2021-05-17 | $41.00K derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | -$255.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $3.00K derived: sum of 2 quarters · filed 2021-03-31 | -$76.00K derived: sum of 3 quarters · filed 2021-03-31 | -$68.00K 10-K · filed 2021-03-31 |
| 2019-09-30 | $258.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $179.00K derived: sum of 2 quarters · filed 2020-11-16 | $187.00K 10-Q · filed 2020-11-16 | $171.00K derived: sum of 4 quarters · filed 2020-11-16 |
| 2019-06-30 | -$79.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | -$71.00K 10-Q · filed 2020-08-14 | -$87.00K derived: sum of 3 quarters · filed 2020-08-14 | -$43.00K derived: sum of 4 quarters · filed 2020-08-14 |
| 2019-03-31 | $8.00K 10-Q · filed 2020-05-14 | -$8.00K derived: sum of 2 quarters · filed 2020-05-14 | $36.00K derived: sum of 3 quarters · filed 2020-05-14 | $30.00K derived: sum of 4 quarters · filed 2020-05-14 |
| 2018-12-31 | -$16.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-03-31 | $28.00K derived: sum of 2 quarters · filed 2020-03-31 | $22.00K derived: sum of 3 quarters · filed 2020-03-31 | -$128.00K 10-K/A · filed 2020-03-31 |
| 2018-09-30 | $44.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $38.00K derived: sum of 2 quarters · filed 2019-11-14 | -$112.00K 10-Q · filed 2019-11-14 | |
| 2018-06-30 | -$6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$156.00K 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | -$150.00K 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |